Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487403 | 1.00 | CNR1 (0.56) | CNR1SIGMAR1OPRD1OPRK1CYP3A4 | |
| SCHEMBL23023068 | 0.91 | SIGMAR1 (0.55) | CNR1SIGMAR1CYP3A4MAPK1KDM4E | |
| SCHEMBL1823141 | 0.91 | SIGMAR1 (0.55) | CNR1SIGMAR1CYP3A4MAPK1KDM4E | |
| SCHEMBL7041284 | 0.91 | SIGMAR1 (0.55) | CNR1SIGMAR1CYP3A4MAPK1KDM4E | |
| SCHEMBL6541038 | 0.89 | CNR1 (0.47) | CNR1OPRD1OPRK1CYP3A4MAPK1 | |
| SCHEMBL28653631 | 0.87 | SIGMAR1 (0.51) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 | |
| SCHEMBL14733411 | 0.87 | SIGMAR1 (0.51) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 | |
| SCHEMBL28653629 | 0.87 | SIGMAR1 (0.51) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 | |
| SCHEMBL6540775 | 0.85 | SIGMAR1 (0.46) | CNR1SIGMAR1CYP3A4MAPK1KDM4E | |
| SCHEMBL10877160 | 0.85 | SMN1; SMN2 (0.51) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20030073846-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-04-17 | — | — | US | disclosed |
| EP-1292564-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
| EP-1140849-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001062705-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-30 | — | — | WO | disclosed |
| WO-2000040560-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073846-A1 | Aminoalcohol derivatives | XDH, ADH1A, ADRB1 | CNR1 71/4885SIGMAR1 53/4885OPRD1 14/4885 |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | CNR1 49/4885SIGMAR1 33/4885OPRD1 17/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | CNR1 41/4885SIGMAR1 51/4885OPRD1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.